Diffuse Large B Cell Lymphoma Market Overview
Following the release of our latest ebook, this is the first blog post in this series focusing on Diffuse Large B Cell Lymphoma, the most common form of Non Hodgkin Lymphoma (NHL). The DLBCL market is experiencing considerable growth; it is predicted to reach a size of almost USD 4.3 billion by 2022.
The insights shared here, and in the eBook that you can download for free 
, are taken from AplusA’s syndicated DLBCL market tracker. The research features insights from at least 100 US and 250 European hematologist / oncologists.